首页/数据集/Characteristics of the CIS and RRMS patients treated by IMD.

Characteristics of the CIS and RRMS patients treated by IMD.

NIAID Data Ecosystem2026-05-16 收录

多发性硬化症治疗

免疫调节药物

数据链接：

https://figshare.com/articles/dataset/Characteristics_of_the_CIS_and_RRMS_patients_treated_by_IMD_/285532 数据链接链接失效反馈

官方服务：

资源简介：

Abbreviations: IM: intramuscular, SC: subcutaneous, IFN: interferon, GA: glatiramer acetate.

应用场景：

创建时间：

2013-02-20

多发性硬化症治疗

药物疗效评估

Objective To assess over 3 years of follow-up, the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension (OLE)

NIAID Data Ecosystem90

Five-years of ocrelizumab in relapsing multiple sclerosis: OPERA studies open-label extension

多发性硬化症治疗

神经免疫临床研究

AbstractObjective To assess over 3 years of follow-up, the effects of maintaining or switching to ocrelizumab (OCR) therapy on clinical and MRI outcomes and safety measures in the open-label extension

DataONE2021-11-29 更新40

Treatment with nanoliposomes loaded with ITE and MOG(35-55) ameliorates EAE

多发性硬化症治疗

药物转录组学

To evaluate the therapeutic potential of NLP(ITE+MOG) in a mouse model of secondary progressive multiple sclerosis, we induced EAE in NOD mice and initiated weekly treatment with nanoliposomes beginni

NIAID Data Ecosystem30

Relations of cognitive measures with clinical disease parameters in paediatric MS patients.

多发性硬化症治疗

认知功能评估

Relations of cognitive measures with clinical disease parameters in paediatric MS patients.

NIAID Data Ecosystem40

Patients with multiple sclerosis (MS) characteristics.

多发性硬化症治疗

神经疾病临床数据

1 Interferon β i.e Betaferon®, Rebif® or Avonex® 2 Glatiramer acetate i.e Copaxone® 3 Cytostatics includes mitoxantrone and cyclophosphamide Patients with multiple sclerosis (MS) characteristics.

NIAID Data Ecosystem30

Characteristics of the CIS and RRMS patients treated by IMD.

资源简介：

相关数据集